Pfizer (PFE)
(Delayed Data from NYSE)
$29.22 USD
-0.05 (-0.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $29.21 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.22 USD
-0.05 (-0.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $29.21 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
Zacks News
Pfizer's (PFE) Talazoparib Emerges Superior in EMBRACA Study
by Zacks Equity Research
Pfizer's (PFE) breast cancer candidate demonstrates superiority over chemotherapy in phase III study in previously treated breast cancer patients.
4 Drug/Biotech Stocks That Could Be Buyout Targets in 2018
by Zacks Equity Research
Biotech mergers and acquisitions, which were quite lean in 2017, may pick up significantly in 2018 if the proposed tax reforms are finally approved.
Pfizer Reports Updated Data from Phase III Study on Ibrance
by Zacks Equity Research
Pfizer (PFE) releases impressive new data of a post-hoc analysis from a phase III study on the combo therapy of Ibrance and Femara for the first-line treatment of ER+, HER2- metastatic breast cancer.
Can Drug/Biotech M&A Rebound Next Year After Bleak 2017?
by Zacks Equity Research
Quite a few pharmaceutical industry mergers may be in the cards in 2018 if the proposed tax reforms are finally approved.
5 Top-Ranked Drug Stocks that are Broker Favorites
by Arpita Dutt
With the pharma and biotech sector bouncing back in 2017, here is a look at five drug stocks including Sarepta (SRPT) that are broker favorites.
Pfizer Wins China & Asia-Pacific Rights to Anti-Fungal Drug
by Zacks Equity Research
Pfizer (PFE) inks a deal to buy exclusive rights to develop and commercialize Basilea Pharmaceutica's anti-fungal treatment, Cresemba, in the Asia-Pacific region and China.
3 Drug/Biotech Stocks in Focus on World AIDS Day
by Zacks Equity Research
On World AIDS Day, we look into some of the key pharma companies in the HIV market that are developing drugs to address the life threatening disease.
Gilead & 3 Other Drug Stocks in Focus this World AIDS Day
by Arpita Dutt
With 36.7 million people living with HIV, there remains significant need for new and improved drugs in this corner of the market that has players like Gilead (GILD).
Glaxo Begins Phase III Study on Injection to Prevent HIV
by Zacks Equity Research
Glaxo (GSK) announces start of a large late-stage African study on an experimental long-acting injection for the prevention of HIV.
Pharma Stock Roundup: Pfizer/Merck KGaA Drug Fails in Study, Teva CEO Announces Changes
by Arpita Dutt
Key highlights this week include changes announced by Teva's CEO and Pfizer (PFE)/Merck KGaA's data presentation. Reports about Amazon's plans to enter the drug market also made headlines.
Glaxo Stock Down So Far This Year: Is a Reversal in Store?
by Zacks Equity Research
Glaxo's shares have declined 7.9% this year so far.
Pfizer/Merck KGaA's Bavencio Fails in Gastric Cancer Study
by Zacks Equity Research
Pfizer & Merck KGaA's (MKGAF) Bavencio/avelumab fails in a phase III study evaluating it for the treatment of gastric cancer in the third-line setting.
Glaxo, Pfizer's ViiV Healthcare Begins HIV Drug Combo Study
by Zacks Equity Research
Glaxo (GSK) and partner Pfizer's ViiV Healthcare commences a phase III study on combo regimen of cabotegravir and rilpivirine for treatment of adults with virally suppressed HIV-1 infection.
2 Large-Cap Drug Stocks Missing Out on Industry Rally in '17
by Zacks Equity Research
Most drug companies with a larger market cap have seen their share price rising this year. However, a couple of large-cap pharma companies have witnessed a downside this year.
3 Companies Competing to Gain Lead in Ovarian Cancer Market
by Zacks Equity Research
Three companies including a major pharma player are developing drugs for the treatment of ovarian cancer using a new technology instead of chemotherapy and competing to gain market share.
Stock Market News For Nov 22, 2017
by Zacks Equity Research
Benchmarks finished in the green on Tuesday following gains in the technology and healthcare sectors
J&J & Glaxo Get FDA Approval for First Two-Drug HIV Regimen
by Zacks Equity Research
J&J (JNJ) and Glaxo received FDA approval for Juluca, a two-drug complete regimen of Tivicay/rilpivirine and Edurant/dolutegravir as a single tablet for the treatment of HIV-1 infection.
Amgen (AMGN) Unveils Auto Injector Device for Enbrel in US
by Zacks Equity Research
Amgen launched its Enbrel Mini with AutoTouch, a new auto injector device for Enbrel in the United States.
Pfizer's Cancer Drug Sutent Gets FDA Nod for Label Expansion
by Zacks Equity Research
Pfizer (PFE) secures an FDA approval for Sutent's label expansion as an adjuvant treatment of recurrent renal cell carcinoma.
Cancer Space Update: Label Expansion for Three Major Drugs
by Zacks Equity Research
This week three major drugs received approval for label expansion in new indications. Moreover, a small biotech launched its first drug as a treatment for kidney cancer.
AstraZeneca's Faslodex Gets FDA Nod for Use With Verzenio
by Zacks Equity Research
AstraZeneca's (AZN) drug Faslodex received FDA approval for a new indication.
Novo Nordisk & 4 Other Pharma Stocks in Focus on World Diabetes Day
by Arpita Dutt
Despite pricing pressure & competition, the diabetes market remains lucrative given the prevalence of the disease and demand for better treatments. Novo Nordisk (NVO) is a key player in this market.
Merck (MRK) Gets CHMP Nod for Infection Candidate Prevymis
by Zacks Equity Research
CHMP has given a positive opinion recommending the marketing approval of Merck's (MRK) Prevymis for the prevention of CMV infection.
The Zacks Analyst Blog Highlights: Pfizer, Occidental Petroleum, Charles Schwab, Prudential and S&P Global
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Occidental Petroleum, Charles Schwab, Prudential and S&P Global
Arena (ARNA) Completes Enrolment in Etrasimod Phase II Study
by Zacks Equity Research
Arena (ARNA) completed full enrollment with 157 patients in a phase II study evaluating etrasimod in ulcerative colitis (UC). Results from the study are expected in the first quarter of 2018.